IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd. (NASDAQ:ICCM) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 89,416 shares, a decline of 87.6% from the May 31st total of 718,392 shares. Approximately 3.3% of the company’s stock are sold short. Based on an average daily trading volume, of 160,692 shares, the short-interest ratio is presently 0.6 days.

Institutional Investors Weigh In On IceCure Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in IceCure Medical in the 4th quarter worth approximately $67,000. Concurrent Investment Advisors LLC bought a new position in shares of IceCure Medical during the 4th quarter valued at $48,000. Finally, Virtu Financial LLC bought a new position in shares of IceCure Medical during the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Analysts Set New Price Targets

ICCM has been the topic of several analyst reports. Maxim Group dropped their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Alliance Global Partners started coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, IceCure Medical currently has a consensus rating of “Hold” and an average target price of $62.70.

IceCure Medical Price Performance

Shares of IceCure Medical stock traded down $1.06 during trading on Friday, hitting $5.96. 771,920 shares of the company’s stock traded hands, compared to its average volume of 10,011,018. IceCure Medical has a 1 year low of $2.12 and a 1 year high of $42.00. The business has a 50-day simple moving average of $6.68 and a 200-day simple moving average of $13.78. The stock has a market capitalization of $16.75 million, a P/E ratio of -0.83 and a beta of 0.40.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). The business had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. On average, equities analysts predict that IceCure Medical will post -3.51 earnings per share for the current fiscal year.

IceCure Medical News Summary

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: IceCure Medical said it has regained compliance with Nasdaq’s minimum bid price requirement, removing a near-term listing concern that can often pressure small-cap stocks. IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: Brookline Capital Markets raised near-term and mid-term EPS estimates for IceCure Medical, including higher forecasts for Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting a slightly better outlook for profitability trends. Icecure Medical Earnings Estimates, EPS & Revenue | NASDAQ:ICCM
• Neutral Sentiment: Short interest fell sharply in mid-June, which can reduce bearish pressure, although there was also a conflicting data entry showing zero shares short, making the signal somewhat unclear.
• Neutral Sentiment: The latest analyst revisions still point to significant losses in the coming years, even though the estimates improved in several periods. This keeps the stock’s longer-term valuation story uncertain.
• Negative Sentiment: IceCure remains unprofitable, and the company previously reported a quarterly EPS loss that missed expectations along with revenue below estimates, which likely continues to weigh on investor sentiment.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.